

# Immunisation schedule Victoria

## Infants and children – July 2018

\*Live attenuated vaccine

Medical risk factors

| Age   | Disease   | Vaccine brand <sup>®</sup>                             | Reconstitute | Site given                             | Route given | Notes  |
|---|---|--|--------------|--|-------------|--|
| <b>Birth</b>  | Hepatitis B   | H-B-Vax-II<br>Paediatric or<br>Engerix-B<br>Paediatric | X            | Anterolateral thigh                    | IM          | Give preferably within 24 hours of birth<br>May be given up to 7 days after birth  |
| <b>2 months (from 6 weeks) and 4 months</b>   | Diphtheria-tetanus-pertussis, poliomyelitis-hepatitis B- <i>Haemophilus influenzae</i> type b | Infanrix <i>hexa</i>                                   | ✓            | Anterolateral thigh                    | IM          |  |
|   | Pneumococcal  | Prevenar 13  | X            | Anterolateral thigh                    | IM          |  |
|   | Rotavirus   | Rotarix*   | X            | Mouth                                  | Oral        | 1st dose must be given before 15 weeks of age<br>2nd dose must be given before 25 weeks of age   |
| <b>6 months</b>   | Diphtheria-tetanus-pertussis-poliomyelitis-hepatitis B- <i>Haemophilus influenzae</i> type b  | Infanrix <i>hexa</i>                                   | ✓            | Anterolateral thigh                    | IM          | Give with an 8-week interval after dose 2 of Infanrix <i>hexa</i> at minimum age of 24 weeks.  |
| <b>6 months of age premature baby &lt; 28 weeks gestation or with medical risk factor</b> | Pneumococcal  | Prevenar 13  | X            | Anterolateral thigh                    | IM          | See current Handbook for children with a medical risk  |
| <b>6 months to &lt;5 years - all infants and children</b>                                 | Influenza   | As supplied  | X            | Anterolateral thigh < 12 months of age | IM          | Annually. In children aged 6 months to less than 9 years of age in the first year of administration, give 2 doses a minimum of 1 month apart<br>Give 0.25ml dose from 6 months to under 3 years of age |

Immunisation Section – Department of Health and Human Services: 1300 882 008  
Australian Immunisation Register: 1800 653 809

National HPV Register: 1800 478 734  
SAEFVIC - Victoria's vaccine safety service: 1300 882 924 #1

## Immunisation schedule Victoria. Infants and children – July 2018 (continued)

\*Live attenuated vaccine

Medical risk factors

| Age   | Disease                                      | Vaccine brand <sup>®</sup>                    | Reconstitute | Site given          | Route given                    | Notes  |
|---|--|---|--------------|---------------------|--------------------------------|--|
| 12 months   | Measles-mumps-rubella                        | Priorix* or M-M-R-II*                         | ✓            | Anterolateral thigh | Priorix SC /IM, M-M-R-II SC    |  |
|   | Meningococcal ACWY                           | Nimenrix                                      | ✓            | Deltoid             | IM                             |  |
|   | Pneumococcal                                 | Prevenar 13                                   | ✗            | Deltoid             | IM                             |  |
| 12 months of age premature baby < 32 weeks gestation or < 2000g birthweight | Hepatitis B                                  | H-B-Vax-II Paediatric or Engerix-B Paediatric | ✗            | Deltoid             | IM                             | single booster dose  |
| 18 months   | Measles-mumps-rubella-varicella (chickenpox) | PriorixTetra* or ProQuad*                     | ✓            | Deltoid             | PriorixTetra SC/IM, Proquad SC | Current handbook recommends 2nd dose of Varilrix <sup>®</sup> /Varivax <sup>®</sup> to reduce incidence of 'breakthrough' varicella. This MUST be on prescription. Minimum 1 month interval for 2 live vaccines. |
|   | Diphtheria-tetanus-pertussis                 | Infanrix or Tripacel                          | ✗            | Deltoid             | IM                             |  |
|   | <i>Haemophilus influenzae</i> type b         | ActHIB  | ✓            | Anterolateral thigh | IM                             |  |
| 4 years   | Diphtheria-tetanus-pertussis-poliomyelitis   | Infanrix IPV or Quadracel                     | ✗            | Deltoid             | IM                             |  |
| 4-5 years of age with medical risk factor                                   | Pneumococcal                                 | Pneumovax 23                                  | ✗            | Deltoid             | IM                             | See current Handbook for recommended additional doses for children at increased risk   |
| BCG for eligible infants and children                                       | Tuberculosis                                 | As supplied                                   |              |                     |                                | BCG* for infants and children under 5 years of age travelling to TB endemic countries  |
| 5 years of age and over with medical risk factor                            | Influenza                                    | Influenza                                     | ✗            | Deltoid             | IM                             | If less than 9 years of age in the first year of administration, give 2 doses a minimum of 1 month apart   |

| Intramuscular injection (IM)          | Needle size          | Angle of needle insertion |
|---------------------------------------|----------------------|---------------------------|
| Infants and children                  | 23G/25G, 25mm length | 90° to skin plane         |
| Pre-term babies and very small babies | 25G/23G, 16mm length | 90° to skin plane         |

| Subcutaneous injection (SC) | Needle size          | Angle of needle insertion |
|-----------------------------|----------------------|---------------------------|
| In all persons              | 25G/26G, 16mm length | 45° to skin plane         |

This schedule is intended as a guide only and complete consultation with The Australian Immunisation Handbook is recommended. For additional information refer to the online edition of the handbook: <http://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home>

# Immunisation schedule Victoria

## Adolescents – July 2018

\*Live attenuated vaccine

Medical risk factors

| Age   | Disease                           | Vaccine brand <sup>®</sup> | Reconstitute | Site given | Route given | Notes  |
|---|-----------------------------------|----------------------------|--------------|------------|-------------|--|
| <b>Year 7 Secondary school (or age equivalent, 12-13 years of age)</b>                              | <i>Human papillomavirus (HPV)</i> | Gardasil 9                 | X            | Deltoid    | IM          | 2 dose course (0, 6-12m) under 15 years & 3 dose course (0, 2m, 6m) if 15 years and over. Major immunocompromising conditions require a 3 dose course. |
|   | Diphtheria-tetanus-pertussis      | Boostrix                   | X            | Deltoid    | IM          |  |
| <b>Year 10 Secondary School (or age equivalent)</b>   | Meningococcal ACWY                | Menactra                   | X            | Deltoid    | IM          | Time limited program ceases 31 December 2018.  |
| <b>15 years of age and over Aboriginal &amp; Torres Strait Islanders</b>                            | Influenza                         | As supplied                | X            | Deltoid    | IM          | Annually   |
| <b>15 years of age and over Aboriginal &amp; Torres Strait Islanders with a medical risk factor</b> | Pneumococcal                      | Pneumovax 23               | X            | Deltoid    | IM          | See current Handbook for recommended additional doses for people at increased risk   |
| <b>Young people with a medical risk factor</b>  | Influenza                         | As supplied                | X            | Deltoid    | IM          | Annually. See current Handbook for identification of people at increased risk  |

| Intramuscular injection (IM) | Needle size          | Angle of needle insertion |
|------------------------------|----------------------|---------------------------|
| Adolescent                   | 23G/25G, 25mm length | 90° to skin plane         |
| Very large adolescent        | 23G/25G, 38mm length | 90° to skin plane         |

| Subcutaneous injection (SC) | Needle size          | Angle of needle insertion |
|-----------------------------|----------------------|---------------------------|
| In all persons              | 25G/26G, 16mm length | 45° to skin plane         |

This schedule is intended as a guide only and complete consultation with The Australian Immunisation Handbook is recommended. For additional information refer to the online edition of the handbook: <http://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home>

# Immunisation schedule Victoria

## Adults – July 2018

\*Live attenuated vaccine

Medical risk factors

| Age  | Disease                      | Vaccine brand <sup>®</sup> | Reconstitute | Site given | Route given | Notes  |
|--|------------------------------|----------------------------|--------------|------------|-------------|--|
| <b>Aboriginal &amp; Torres Strait Islanders with a medical risk factor</b> | Pneumococcal                 | Pneumovax 23               | X            | Deltoid    | IM          | See current Handbook for recommended additional doses for people at increased risk   |
| <b>Aboriginal &amp; Torres Strait Islanders</b>                            | Influenza                    | As supplied                | X            | Deltoid    | IM          | Annually   |
|  | Hepatitis B                  |                            |              |            |             |  |
| <b>Pregnant women</b>  | Influenza                    | As supplied                | X            | Deltoid    | IM          | At any stage of pregnancy  |
|  | Diphtheria-tetanus-pertussis | Adacel or Boostrix         | X            | Deltoid    | IM          | Pregnant women from 28 weeks gestation during every pregnancy<br>Partners of women who are at least 28 weeks pregnant if the partner has not received a pertussis booster in the last ten years.<br>Parents/guardians of a baby under 6 months of age and they have not received a pertussis booster in the last 10 years. |
| <b>People with a medical risk factor</b>                                   | Influenza                    | As supplied                | X            | Deltoid    | IM          | Annually. See current Handbook for identification of people at increased risk  |
| <b>From 50 years of age Aboriginal &amp; Torres Strait Islanders</b>       | Pneumococcal                 | Pneumovax 23               | X            | Deltoid    | IM          | See current Handbook for recommended additional doses for people at increased risk   |
| <b>From 65 years</b>   | Influenza                    | As supplied                | X            | Deltoid    | IM          | Annually. Use high-immunogenicity formulations   |
|  | Pneumococcal                 | Pneumovax 23               | X            | Deltoid    | IM          | See current Handbook for recommended additional doses for people at increased risk   |
| <b>70 years or from 71 to 79 years (until the end of 2021)</b>             | Shingles (Herpes Zoster)     | Zostavax                   | ✓            | Deltoid    | SC          | Single dose unless contra-indicated  |

| Intramuscular injection (IM) | Needle size          | Angle of needle insertion |
|------------------------------|----------------------|---------------------------|
| Adults                       | 23G/25G, 25mm length | 90° to skin plane         |
| Very large adult             | 23G/25G, 38mm length | 90° to skin plane         |

| Subcutaneous injection (SC) | Needle size          | Angle of needle insertion |
|-----------------------------|----------------------|---------------------------|
| In all persons              | 25G/26G, 16mm length | 45° to skin plane         |

This schedule is intended as a guide only and complete consultation with The Australian Immunisation Handbook is recommended. For additional information refer to the online edition of the handbook: <http://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home>



Health and Human Services

# Immunisation schedule Victoria

## Additional at risk groups – July 2018

\*Live attenuated vaccine Medical risk factors

| Group   | Disease                          | Vaccine brand <sup>®</sup>   | Reconstitute  | Site given    | Route given                | Notes  |
|---|----------------------------------|------------------------------|---------------|---------------|----------------------------|--|
| <b>Women planning pregnancy or after delivery</b>           | Measles-mumps-rubella            | Priorix*                     | ✓             | Deltoid       | Priorix SC/IM, M-M-R-II SC | Rubella non-immune women planning pregnancy or shortly after delivery  |
| <b>**Vulnerable citizens</b>                                | Age appropriate vaccine catch-up | As supplied                  | As applicable | As applicable | As applicable              | Eligible for NIP and Victorian funded immunisation programs  |
| <b>Hepatitis B vaccine for eligible people at risk</b>      | Hepatitis B                      | Engerix-B (paediatric/adult) | X             | Deltoid       | IM                         | All non immune Aboriginal and Torres Strait Islander people<br>Household contacts or sexual partners of people living with hepatitis B infection<br>People who inject drugs or are on opioid substitution therapy<br>People living with hepatitis C<br>Men who have sex with men<br>People living with HIV<br>Prisoners and remandees<br>People no longer in a custodial setting who commenced but did not complete the vaccine course while in custody<br>People from endemic countries and who arrived in Australia in the last 10 years. (Priority countries include China, Philippines, Malaysia, Vietnam, Afghanistan, Thailand, South Korea, Myanmar (Burma) Indonesia, Singapore, Hong Kong, Taiwan and Cambodia) |
| <b>**Rabies vaccine for eligible people at risk</b>         | Rabies                           | As supplied                  | ✓             | Deltoid       | IM                         | Volunteer handler of Australian bats in Victoria for the primary course<br>Post exposure prophylaxis   |
| <b>Men who have sex with men</b>                            | Meningococcal                    | Menactra                     | X             | Deltoid       | IM                         | Time limited program to finish on 31 December 2018   |
|   | Human Papillomavirus             | Gardasil                     | X             | Deltoid       | IM                         | Time limited program to finish on 31 December 2018   |
|   | Hepatitis A                      | Havrix 1440                  | X             | Deltoid       | IM                         | Time limited program to finish on 31 December 2018   |
| <b>People who have injected drugs in the past 12 months</b> | Hepatitis A                      | Havrix 1440                  | X             | Deltoid       | IM                         | Time limited program to finish on 31 December 2018   |

| Intramuscular injection (IM)        | Needle size          | Angle of needle insertion |
|-------------------------------------|----------------------|---------------------------|
| In all persons                      | 23G/25G, 25mm length | 90° to skin plane         |
| Pre-term babies & very small babies | 25G/23G, 16mm length | 90° to skin plane         |
| Very large person                   | 23G/25G, 38mm length | 90° to skin               |

| Subcutaneous injection (SC) | Needle size          | Angle of needle insertion |
|-----------------------------|----------------------|---------------------------|
| In all persons              | 25G/26G, 16mm length | 45° to skin plane         |

This schedule is intended as a guide only and complete consultation with The Australian Immunisation Handbook is recommended. For additional information refer to the online edition of the handbook: <http://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home>